INT314337

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 6
Disease Relevance 5.24
Pain Relevance 0.80

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

TRGC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 88 96.12 Very High Very High Very High
spinal inflammation 23 77.36 Quite High
Pain 25 65.92 Quite High
endometriosis 12 65.12 Quite High
opiate 4 44.08 Quite Low
ischemia 8 35.68 Quite Low
rheumatoid arthritis 7 29.04 Quite Low
agonist 8 10.24 Low Low
analgesia 4 7.72 Low Low
abdominal pain 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 27 99.88 Very High Very High Very High
Hereditary Angioedema 197 99.64 Very High Very High Very High
Pressure And Volume Under Development 86 97.84 Very High Very High Very High
Cancer 3 97.56 Very High Very High Very High
Non-small-cell Lung Cancer 6 92.20 High High
Emergencies 21 91.56 High High
Toxicity 4 88.36 High High
Angioedema 42 80.76 Quite High
Laryngeal Edema 16 79.24 Quite High
Low Back Pain 23 77.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Prophylaxis for HAE attacks is available; either with attenuated androgens which increase hepatic production of endogenous C1 inhibitor, or by antifibrinolytics such as tranexamic acid or ??
Negative_regulation (inhibitor) of Gene_expression (production) of C1 associated with hereditary angioedema
1) Confidence 0.52 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 1.37 Pain Relevance 0.06
Nearly all other cases are type 2 HAE, which is characterized by the expression of dysfunctional C1 inhibitor.
Negative_regulation (inhibitor) of Gene_expression (expression) of C1 associated with hereditary angioedema
2) Confidence 0.50 Published 2010 Journal BMC Blood Disord Section Body Doc Link PMC2881905 Disease Relevance 1.02 Pain Relevance 0.12
Rhucin, a recombinant C1 inhibitor, given intravenously, is also currently unlicensed.52–54
Negative_regulation (inhibitor) of Gene_expression (is) of C1
3) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.80 Pain Relevance 0.12
While not being directly comparable, results of studies of C1 inhibitor in acute HAE suggest that the icatibant and C1 inhibitor are broadly similar in terms of onset of relief and time to complete resolution of symptoms.15–18,40
Negative_regulation (inhibitor) of Gene_expression (icatibant) of C1 associated with hereditary angioedema
4) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.48 Pain Relevance 0.07
Despite only recently gaining a licence in many EU countries and in the US, C1 inhibitor has been used extensively for HAE and has an impressive record.22,54,61,62 It seems likely that both C1 inhibitor and icatibant will be used, perhaps at different times in the same patient, according to circumstances.
Negative_regulation (inhibitor) of Gene_expression (used) of C1 associated with hereditary angioedema
5) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941790 Disease Relevance 0.33 Pain Relevance 0.07
Additionally, we observed that in some diseases, the effect of C1 and C2 phenotypes or genotypes seemed to be detectable only in the absence of KIR2DS5 gene but was visible only in its presence in other diseases.
Negative_regulation (effect) of Gene_expression (phenotypes) of C1 associated with disease
6) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2928722 Disease Relevance 1.24 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox